Response Time and BRAF Status Factor Into IO Selection for Melanoma
Source: Targeted Oncology, January 2025
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
DISCUSSION QUESTIONS
- What are important efficacy and safety data for you from the RELATIVITY-047 trial (NCT03470922) of nivolumab/relatlimab (Opdualag)?
- How do you balance efficacy, safety, patient preference, goals of therapy, and quality of life when recommending a first-line regimen?
Thach-Giao Truong, MD: When you look at this trial, what stands out to you in terms of efficacy vs safety?